Physician profile
Mark L Monteferrante
NPI 1780665851
$2,673.93
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,601 · 2020: $219 · 2021: $56.19 · 2022: $231 · 2023: $306 · 2024: $261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $566.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,543.86 | 2019-2024 | Austedo Xr, Ajovy, Austedo |
| Hitachi Healthcare Americas Corp. | $506.67 | 2019 | |
| Sunovion Pharmaceuticals INC. | $236.29 | 2019-2021 | |
| Bracco Diagnostics INC. | $122.20 | 2023 | |
| Siemens Medical Solutions USA, INC. | $79.70 | 2020-2024 | |
| Genzyme Corporation | $45.51 | 2019 | |
| Acorda Therapeutics, INC | $36.77 | 2020 | |
| Biogen, INC. | $24.54 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $21.55 | 2020 | |
| Lilly USA, LLC | $20.53 | 2023 | Amyvid |
| Alnylam Pharmaceuticals INC. | $19.35 | 2019 | |
| Emd Serono, INC. | $16.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Monteferrante listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.